DK2909182T3 - Fremstilling af og formulering omfattende en mek-inhibitor - Google Patents

Fremstilling af og formulering omfattende en mek-inhibitor Download PDF

Info

Publication number: DK2909182T3
Authority: DK; Denmark
Prior art keywords: preparation; mek inhibitor; formulation including; formulation; mek
Prior art date: 2012-10-19

Application number

DK13847106.5T

Other languages

English (en)

Inventor

Weidong Liu

Peter J Stengel

Paul Nichols

Christoph Max Krell

Daniel Andreas Niederer

Werner Heinz Pachinger

Daniel Zimmermann

Marian Misun

Marie-Christine Wolf

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-19

Filing date

2013-10-18

Publication date

2020-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50488781&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2909182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-18 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2020-02-17 Application granted granted Critical

2020-02-17 Publication of DK2909182T3 publication Critical patent/DK2909182T3/da

Links

229940124647 MEK inhibitor Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Metallurgy (AREA)
Oil, Petroleum & Natural Gas (AREA)
Crystallography & Structural Chemistry (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK13847106.5T 2012-10-19 2013-10-18 Fremstilling af og formulering omfattende en mek-inhibitor DK2909182T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261716169P	2012-10-19	2012-10-19
PCT/US2013/065633 WO2014063024A1 (en)	2012-10-19	2013-10-18	Preparation of and formulation comprising a mek inhibitor

Publications (1)

Publication Number	Publication Date
DK2909182T3 true DK2909182T3 (da)	2020-02-17

Family

ID=50488781

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19211405.6T DK3702351T3 (da)	2012-10-19	2013-10-18	Formulering omfattende en mek-inhibitor
DK13847106.5T DK2909182T3 (da)	2012-10-19	2013-10-18	Fremstilling af og formulering omfattende en mek-inhibitor

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19211405.6T DK3702351T3 (da)	2012-10-19	2013-10-18	Formulering omfattende en mek-inhibitor

Country Status (23)

Country	Link
US (7)	US9238627B2 (da)
EP (3)	EP4306171A3 (da)
JP (3)	JP6385939B2 (da)
CN (3)	CN109456272A (da)
AR (1)	AR099630A1 (da)
BR (1)	BR112015008623B1 (da)
CA (2)	CA2888474C (da)
CY (1)	CY1122670T1 (da)
DK (2)	DK3702351T3 (da)
ES (2)	ES2971077T3 (da)
FI (1)	FI3702351T3 (da)
HK (1)	HK1214254A1 (da)
HR (1)	HRP20240033T1 (da)
HU (2)	HUE065433T2 (da)
JO (1)	JOP20130304B1 (da)
LT (1)	LT3702351T (da)
PL (2)	PL3702351T3 (da)
PT (2)	PT2909182T (da)
RS (1)	RS65117B1 (da)
RU (2)	RU2669391C2 (da)
SI (2)	SI2909182T1 (da)
TW (1)	TWI650316B (da)
WO (1)	WO2014063024A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20240033T1 (hr)	2012-10-19	2024-03-29	Array Biopharma, Inc.	Formulacija koja sadrži inhibitor mek
CN105566225A (zh) *	2015-02-16	2016-05-11	苏州晶云药物科技有限公司	一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2017210538A1 (en) *	2016-06-03	2017-12-07	Giordano Caponigro	Pharmaceutical combinations
WO2019096112A1 (zh) *	2017-11-14	2019-05-23	深圳市塔吉瑞生物医药有限公司	一种取代的苯并咪唑化合物及包含该化合物的组合物
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
WO2019139970A1 (en) *	2018-01-09	2019-07-18	Duke University	Topical administration of mek inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) *	2019-04-16	2020-10-22	Alembic Pharmaceuticals Limited	Process of preparation of benzimidazole compounds
WO2021116901A1 (en) *	2019-12-09	2021-06-17	Biocon Limited	Forms of binimetinib and process for preparation thereof
EP4225307A1 (en)	2020-10-05	2023-08-16	Pierre Fabre Medicament	Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN112679438A (zh) *	2020-12-31	2021-04-20	武汉九州钰民医药科技有限公司	制备司美替尼的方法
WO2023084489A1 (en)	2021-11-15	2023-05-19	Pfizer Inc.	Methods of treating coronavirus disease 2019
WO2024003942A1 (en) *	2022-07-01	2024-01-04	Natco Pharma Limited	An improved process for the preparation of selumetinib sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20012498A3 (cs) *	1999-01-13	2002-08-14	Warner-Lambert Company	Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK
CN1358094A (zh) *	1999-07-16	2002-07-10	沃尼尔·朗伯公司	用mek抑制剂治疗慢性疼痛的方法
DK1482932T3 (da)	2002-03-13	2010-02-01	Array Biopharma Inc	N3-alkylerede benzimidazolderivater som MEK-inhibitorer
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
MXPA06000921A (es) *	2003-07-24	2006-03-30	Warner Lambert Co	Derivados de benzamidazoles como inhibidores de mek.
ES2567133T3 (es)	2005-06-23	2016-04-20	Array Biopharma, Inc.	Proceso para preparar compuestos de benzoimidazol
JP5237797B2 (ja)	2005-06-23	2013-07-17	アレイバイオファーマ、インコーポレイテッド	ベンゾイミダゾール化合物を調製するためのＳＮＡｒ法
WO2009018233A1 (en) *	2007-07-30	2009-02-05	Ardea Biosciences, Inc.	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US20090030058A1 (en) *	2005-12-21	2009-01-29	Mohammed Pervez	Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
JP5453290B2 (ja) *	2007-11-12	2014-03-26	武田薬品工業株式会社	Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
BRPI0925050A2 (pt) *	2009-04-21	2015-08-04	Novartis Ag	Compostos heterocíclicos como inibidores de mek
HRP20240033T1 (hr)	2012-10-19	2024-03-29	Array Biopharma, Inc.	Formulacija koja sadrži inhibitor mek

2013
- 2013-10-18 HR HRP20240033TT patent/HRP20240033T1/hr unknown
- 2013-10-18 PL PL19211405.6T patent/PL3702351T3/pl unknown
- 2013-10-18 DK DK19211405.6T patent/DK3702351T3/da active
- 2013-10-18 DK DK13847106.5T patent/DK2909182T3/da active
- 2013-10-18 SI SI201331672T patent/SI2909182T1/sl unknown
- 2013-10-18 RU RU2015118572A patent/RU2669391C2/ru active
- 2013-10-18 HU HUE19211405A patent/HUE065433T2/hu unknown
- 2013-10-18 AR ARP130103796A patent/AR099630A1/es not_active Application Discontinuation
- 2013-10-18 TW TW102137813A patent/TWI650316B/zh active
- 2013-10-18 CA CA2888474A patent/CA2888474C/en active Active
- 2013-10-18 RS RS20240112A patent/RS65117B1/sr unknown
- 2013-10-18 WO PCT/US2013/065633 patent/WO2014063024A1/en active Application Filing
- 2013-10-18 CN CN201810684986.7A patent/CN109456272A/zh active Pending
- 2013-10-18 HU HUE13847106A patent/HUE047708T2/hu unknown
- 2013-10-18 PT PT138471065T patent/PT2909182T/pt unknown
- 2013-10-18 JP JP2015538050A patent/JP6385939B2/ja active Active
- 2013-10-18 CN CN201380063271.5A patent/CN104870427B/zh active Active
- 2013-10-18 EP EP23211278.9A patent/EP4306171A3/en active Pending
- 2013-10-18 US US14/057,498 patent/US9238627B2/en active Active
- 2013-10-18 EP EP19211405.6A patent/EP3702351B1/en active Active
- 2013-10-18 LT LTEP19211405.6T patent/LT3702351T/lt unknown
- 2013-10-18 CA CA3079071A patent/CA3079071C/en active Active
- 2013-10-18 RU RU2018127873A patent/RU2018127873A/ru not_active Application Discontinuation
- 2013-10-18 PL PL13847106T patent/PL2909182T3/pl unknown
- 2013-10-18 PT PT192114056T patent/PT3702351T/pt unknown
- 2013-10-18 ES ES19211405T patent/ES2971077T3/es active Active
- 2013-10-18 ES ES13847106T patent/ES2772498T3/es active Active
- 2013-10-18 SI SI201332074T patent/SI3702351T1/sl unknown
- 2013-10-18 CN CN201811124073.6A patent/CN109336824B/zh active Active
- 2013-10-18 EP EP13847106.5A patent/EP2909182B1/en active Active
- 2013-10-18 FI FIEP19211405.6T patent/FI3702351T3/fi active
- 2013-10-18 BR BR112015008623-3A patent/BR112015008623B1/pt active IP Right Grant
- 2013-10-20 JO JOP/2013/0304A patent/JOP20130304B1/ar active
2015
- 2015-12-18 US US14/974,655 patent/US9562016B2/en active Active
- 2015-12-18 US US14/974,588 patent/US9382212B1/en active Active
2016
- 2016-02-25 HK HK16102126.5A patent/HK1214254A1/zh unknown
- 2016-02-25 US US15/053,441 patent/US9598376B2/en active Active
2017
- 2017-02-28 US US15/445,393 patent/US9980944B2/en active Active
- 2017-12-14 US US15/842,715 patent/US10398683B2/en active Active
2018
- 2018-06-07 JP JP2018109486A patent/JP6737838B2/ja active Active
2019
- 2019-07-16 US US16/512,823 patent/US10729678B2/en active Active
- 2019-08-19 JP JP2019149828A patent/JP2019194272A/ja active Pending
2020
- 2020-02-18 CY CY20201100148T patent/CY1122670T1/el unknown

Also Published As

Publication number	Publication date
US20160168102A1 (en)	2016-06-16
EP4306171A2 (en)	2024-01-17
CN109456272A (zh)	2019-03-12
PT3702351T (pt)	2024-01-17
JP2018135399A (ja)	2018-08-30
AR099630A1 (es)	2016-08-10
CY1122670T1 (el)	2021-03-12
SI3702351T1 (sl)	2024-03-29
JP6737838B2 (ja)	2020-08-12
ES2971077T3 (es)	2024-06-03
RU2018127873A (ru)	2019-03-14
CA3079071C (en)	2022-06-07
FI3702351T3 (fi)	2024-01-24
RS65117B1 (sr)	2024-02-29
DK3702351T3 (da)	2024-01-29
BR112015008623A2 (pt)	2017-07-04
CN109336824A (zh)	2019-02-15
TW201427956A (zh)	2014-07-16
PT2909182T (pt)	2020-03-02
US20180296533A1 (en)	2018-10-18
JP6385939B2 (ja)	2018-09-05
US20160168104A1 (en)	2016-06-16
US9382212B1 (en)	2016-07-05
WO2014063024A1 (en)	2014-04-24
EP3702351A1 (en)	2020-09-02
TWI650316B (zh)	2019-02-11
LT3702351T (lt)	2024-01-10
PL2909182T3 (pl)	2020-06-01
HUE065433T2 (hu)	2024-05-28
BR112015008623B1 (pt)	2022-10-25
CA3079071A1 (en)	2014-04-24
US20200171002A1 (en)	2020-06-04
PL3702351T3 (pl)	2024-04-02
EP2909182A1 (en)	2015-08-26
EP2909182B1 (en)	2019-12-04
JP2019194272A (ja)	2019-11-07
JP2016503391A (ja)	2016-02-04
US20160168103A1 (en)	2016-06-16
JOP20130304B1 (ar)	2021-08-17
CA2888474A1 (en)	2014-04-24
HUE047708T2 (hu)	2020-05-28
EP2909182A4 (en)	2016-07-06
HK1214254A1 (zh)	2016-07-22
US9238627B2 (en)	2016-01-19
US20170231963A1 (en)	2017-08-17
US20140128442A1 (en)	2014-05-08
US9598376B2 (en)	2017-03-21
EP3702351B1 (en)	2023-11-22
RU2015118572A (ru)	2016-12-20
CN104870427B (zh)	2018-10-23
CN104870427A (zh)	2015-08-26
ES2772498T3 (es)	2020-07-07
RU2669391C2 (ru)	2018-10-11
HRP20240033T1 (hr)	2024-03-29
EP4306171A3 (en)	2024-04-03
US10398683B2 (en)	2019-09-03
CA2888474C (en)	2021-03-02
US10729678B2 (en)	2020-08-04
US9980944B2 (en)	2018-05-29
US9562016B2 (en)	2017-02-07
SI2909182T1 (sl)	2020-03-31
CN109336824B (zh)	2022-11-11

Publication	Publication Date	Title
DK2909182T3 (da)	2020-02-17	Fremstilling af og formulering omfattende en mek-inhibitor
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK3725778T3 (da)	2021-09-20	Formuleringer af enzalutamid
DK3415157T3 (da)	2020-10-19	N-acyldipeptidderivater og anvendelser deraf
DK2920149T3 (da)	2019-07-01	3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2609956T3 (da)	2019-06-03	Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde
BR112015003153A2 (pt)	2017-07-04	baricitinib deuterado
BR302012005979S1 (pt)	2014-10-29	Configuração aplicada a cadeira
BR112014011282A2 (pt)	2017-05-02	dispositivo escravo e rede
DK2933685T3 (da)	2019-07-22	Procespatron og billeddannelsesindretning
DK2917181T3 (da)	2020-01-13	Heteroarylderivater og anvendelser deraf
DK3326642T3 (da)	2021-02-22	Langtidsvirkende koagulationsfaktorer og brugen deraf
CO6870048A2 (es)	2014-02-20	Formulación herbicida mejorada
DK3392252T3 (da)	2024-01-08	Pyrimido-pyridazinonforbindelser og deres anvendelse
SMT201700046B (it)	2017-03-08	Micobatterio ricombinante come vaccino
DK2704744T3 (da)	2019-07-15	Komplementfaktor-b-analoger og anvendelser deraf
BR112015007217A2 (pt)	2017-08-08	compostos e usos do composto
DK2849798T3 (da)	2021-05-31	Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
CL2015000638A1 (es)	2015-08-28	Composiciones herbicidas que contienen aminopiralid y triclopir
DK2943460T3 (da)	2020-03-16	6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK2672837T4 (da)	2022-09-26	Ernæringssammensætning og anvendelser deraf
FR2998538B1 (fr)	2015-08-07	Trampoline amphibie
DK2882681T3 (da)	2019-07-01	Anordning og fremgangsmåde til overføring af fjedre
DK2906237T3 (da)	2020-07-13	Multivalent heteromultimer scaffold design og konstrukter